{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:50:20Z","timestamp":1782172220368,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.diagmicrobio.2020.115195","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T11:25:51Z","timestamp":1598613951000},"page":"115195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, \u03b2-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017\u20132019"],"prefix":"10.1016","volume":"99","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0005","first-page":"1","article-title":"Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)","volume":"14","author":"Bai","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0010","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/14656566.2019.1675637","article-title":"Important new therapies for methicillin-resistant Staphylococcus aureus","volume":"20","author":"Bassetti","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0015","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0020","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: Eleventh edition","article-title":"M07Ed11","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0025","series-title":"Performance standards for antimcirobial susceptibility testing: 30th informational supplement","article-title":"M100Ed30","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0030","series-title":"Package insert","author":"Dalvance\u2122","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0035","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-016-0666-0","article-title":"Single-dose dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0045","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0050","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against gram-positive cocci from clinical infections in the USA and Europe 2015-16","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0055","author":"USFDA"},{"key":"10.1016\/j.diagmicrobio.2020.115195_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa293","article-title":"Use of a standardized dalbavancin approach to facilitate earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy","volume":"7","author":"Vazquez Deida","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320305721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889320305721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:54:39Z","timestamp":1760003679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889320305721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0732889320305721"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115195","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, \u03b2-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017\u20132019","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115195"}}